[1] JAHANGIR A,HOU J,HONG C.Role of micro-RNAs in drug resistance of multiple myeloma[J].Oncotarget,2016,37(7):60723-60735.
[2] ZHAO J J,CHU Z B,HU Y,et al.Targeting the miR-221-222/PUMA/BAK/BAX pathway abrogates dexamethasone resistance in multiple myeloma[J].Cancer Res,2015,75(20):4384-4397.
[3] MIRZAEI H R,SAHEBKAR A,MOHAMMADI M,et al.Circulating microRNAs in Hepatocellular Carcinoma:Potential Diagnostic and Prognostic Biomarkers[J].Curr Pharm Des,2016,22(34):5257-5269.
[4] SEKAR D,KRISHNAN R,THIRUGNANASAMBANTHAM K,et al.Significance of microRNA 21 in gastric cancer[J].Clin Res Hepatol Gastroenterol,2016,40(5):538-545.
[5] OKUGAWA Y,YAO L,TOIYAMA Y,et al.Prognostic impact of sarcopenia and its correlation with circulating miR-21 in colorectal cancer patients[J].Oncol Rep,2018,39(4):1555-1564.
[6] MUSILOVA K,MRAZ M.MicroRNAs in B-cell lymphomas:how a complex biology gets more complex[J].Leukemia,2015,29(5):1004-1017.
[7] LEI W,WANG S,YANG C,et al.Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma[J].Sci Rep,2016,6(8):32174.
[8] RANINGA P V,di TRAPANI G,VUCKOVIC S,et al.Targeted knockdown of DJ-1 induces multiple myeloma cell death via KLF6 upregulation[J].Apoptosis,2016,21(12):1422-1437.
[9] YVONNE T,LEV K,LEONARDO S,et al.Coding-independent regulation of the tumor suppressor PTEN by competing endogenous mRNAs[J].Cell,2011,147(2):344-357.
[10] 黄海进,徐广峰,焦峰.hsa-miR-21的生物信息学特征分析[J].东南大学学报(医学版),2013,32(1):60-64.
[11] 王金行,丁奇,周雯雯,等.miR-21下调SPRY2表达对多发性骨髓瘤细胞增殖和侵袭能力的影响及其机制研究[J].现代肿瘤医学,2015,23(2):157-162.
[12] 孙利华,汪蕾.miRNA-21靶向调控子宫内膜癌PTEN基因MRE-21片段的研究[J].现代医学,2017,45(10):1442-1446.
[13] URBANEK P,KLOTA L O.Posttranscriptional regulation of FOXO expression:microRNAs and beyond[J].Br J Phamacol,2017,174(12):1514-1532. |